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Background: Roux-en-Y gastric bypass (RYGB) reduces weight and cardiovascular (CV) risk in obese patients. The mechanisms of CV protection 
after RYGB are still unclear but may be partly weight-independent. Glucagon like peptide-1 (GLP-1) exerts endothelial protective actions through 
endothelial-NO-synthase (eNOS) activation. Here, we investigated the role of GLP-1 in obesity-induced endothelial dysfunction in rats after RYBG 
prior to significant weight loss.
methods: After 7 weeks on a high-fat high-cholesterol diet, male Wistar rats underwent RYGB or sham surgery. Sham rats were fed ad lib (AL) 
or body weight-matched (BWM) to RYGB. Thoracic aortic rings were collected 8 days post-surgery and suspended for isometric tension recording. 
Cumulative relaxation responses were performed to peptide GLP-1 (7-36) amide (10-12 to 10-6mol/L) after submaximal contraction with 
norepinephrine (10-6mol/L), and after preincubation with the GLP-1 antagonist exendin (9-39) (10-7 mol/L) or the eNOS-inhibitor L-NAME 
(10-4mol/L). Western blot of aortic lysates using GLP-1 receptor and eNOS antibodies was performed to address the role of GLP-1 signaling in 
endothelial function. Fasting plasma GLP-1 was measured.
results: On day 8 post-surgery, the weight difference among the 3 groups was not yet significant. GLP-1-induced vasorelaxation was impaired in 
sham AL and BWM compared with RYGB rats (max relaxations: 17±3.1 % vs 15±2.8 vs 36±4.8, resp., n=6-8, p<0.05). Exendin (9-39) and L-NAME 
inhibited GLP-1-induced vasodilation, suggesting a mechanism requiring GLP-1 receptor and eNOS activation. GLP-1 receptor protein expression was 
lower in aortic lysates from sham AL and BWM compared to RYGB (0.44±0.1 vs 0.49±0.1 vs 0.86±0.2 relative units, p<0.05); eNOS expression was 
also reduced (0.45±0.1 vs 0.34±0.1 vs 0.74±0.1). Plasma fasting levels of GLP-1 were increased in rats after RYGB compared to sham AL and BWM 
(0.8±0.1 vs 2.0±0.9 vs 10±2.8 pg/ml, p<0.05).
conclusions: Our study suggests that GLP-1 may be a crucial mediator of the endothelial function improvement observed immediately after RYGB, 
indicating a new potential mechanism for the CV protective effects of RYGB, in addition to weight loss.
